Increased angiotensin-receptor blocking is not the first option (original) (raw)

Proteinuria

Nature Reviews Nephrology volume 5, pages 367–368 (2009)Cite this article

Candesartan doses in excess of the recommended antihypertensive maxima have been reported to lead to greater reductions of proteinuria than the advised doses. High-dose angiotensin-converting-enzyme inhibitors, however, are at least as effective as high-dose angiotensin blockers and less expensive. Angiotensin-converting-enzyme inhibition is thus the first-line strategy to halt kidney disease progression.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$189.00 per year

only $15.75 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1: Algorithm for the treatment of patients with proteinuric kidney disease.

References

  1. Burgess, E. et al. Supramaximal dose of candesartan in proteinuric renal disease. J. Am. Soc. Nephrol. doi:10.1681/ASN.2008040416 (2009).
  2. Hollemberg, N. K. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J. Hypertens. 25, 1921–1926 (2007).
    Article Google Scholar
  3. Remuzzi, G., Benigni, A. & Remuzzi, A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288–296 (2006).
    Article CAS Google Scholar
  4. Ruggenenti, P., Perna, A., Remuzzi, G. & GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 63, 2254–2261 (2003).
    Article CAS Google Scholar
  5. Ruggenenti, P., Perna, A., Gherardi, G., Benini, R. & Remuzzi, G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney Dis. 35, 1155–1165 (2000).
    Article CAS Google Scholar
  6. Hou, F. F. et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 18, 1889–1898 (2007).
    Article CAS Google Scholar
  7. Ruggenenti, P. et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 107, 586–592 (2003).
    Article CAS Google Scholar
  8. Catapano, F. et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am. J. Kidney Dis. 52, 475–485 (2008).
    Article Google Scholar
  9. Campbell, R. et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 63, 1094–1103 (2003).
    Article CAS Google Scholar
  10. Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213–1224 (2008).
    Article Google Scholar

Download references

Author information

Author notes

  1. G. Remuzzi, “Mario Negri” Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni 11, 24125 Bergamo, Italy gremuzzi@marionegri.it

Authors and Affiliations

  1. Clinical Research Center for Rare Diseases 'Aldo & Cele Daccò' and Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Piero Ruggenenti, Paolo Cravedi & Giuseppe Remuzzi

Authors

  1. Piero Ruggenenti
  2. Paolo Cravedi
  3. Giuseppe Remuzzi

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

About this article

Cite this article

Ruggenenti, P., Cravedi, P. & Remuzzi, G. Increased angiotensin-receptor blocking is not the first option.Nat Rev Nephrol 5, 367–368 (2009). https://doi.org/10.1038/nrneph.2009.77

Download citation

This article is cited by